Drug Profile

IAM 1363

Alternative Names: ENT H1; IAM-1363; IAM-H1

Latest Information Update: 30 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Iambic Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action ERBB 2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Cancer

Most Recent Events

21 Oct 2025 Iambic Therapeutics enters into a research collaboration and drug supply agreement with Jazz Pharmaceuticals for IAM 1363 and Zanidatamab combination cohort in HER2-positive breast cancer
20 Oct 2025 Interim efficacy data from a phase-I trial in Cancer released by Iambic Therapeutics
17 Oct 2025 Safety and efficacy data from a phase-I clinical trials in Cancer presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com